3-hydroxymethyl-2-pyridinecarboxamide | 115012-12-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-hydroxymethyl-2-pyridinecarboxamide
• 英文别名: 3-(Hydroxymethyl)picolinamide；3-(hydroxymethyl)pyridine-2-carboxamide
• CAS: 115012-12-9
• 化学式: C₇H₈N₂O₂
• mdl: MFCD18802493
• 分子量: 152.153
• InChiKey: QXNKFORAXSMERU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  76.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-hydroxymethyl-2-pyridinecarboxamide 在 盐酸 作用下， 以 甲醇 、 水 为溶剂， 反应 1.5h， 以72%的产率得到呋喃并[3,4-b]吡啶-5(7H)-酮
  参考文献：
  名称：

  The Thermally-Controlled Chemoselective Reduction of 5H-Pyrrolo[3,4-b]pyridine-5,7(6H)-dione with Sodium Borohydride

  摘要：

  标题反应在室温或-20°C下分别生成2-（羟甲基）尼古酰胺或6,7-二氢-7-羟基-5H-吡咯并[3,4-b]吡啶-5-酮作为主要产物，同时伴有相应的区域异构体作为次要产物。这些新型化合物被转化为已知化合物，以确定其异构结构。

  DOI：

  10.1246/bcsj.60.4178
• 作为产物：
  描述：

  5-羟基-5,6-二氢-7H-吡咯并[3,4-b]吡啶-7-酮 在 sodium tetrahydroborate 作用下， 以 甲醇 、 氯仿 为溶剂， 反应 1.0h， 以99%的产率得到3-hydroxymethyl-2-pyridinecarboxamide
  参考文献：
  名称：

  The Thermally-Controlled Chemoselective Reduction of 5H-Pyrrolo[3,4-b]pyridine-5,7(6H)-dione with Sodium Borohydride

  摘要：

  标题反应在室温或-20°C下分别生成2-（羟甲基）尼古酰胺或6,7-二氢-7-羟基-5H-吡咯并[3,4-b]吡啶-5-酮作为主要产物，同时伴有相应的区域异构体作为次要产物。这些新型化合物被转化为已知化合物，以确定其异构结构。

  DOI：

  10.1246/bcsj.60.4178

文献信息

• [EN] PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE<br/>[FR] COMPOSÉS À BASE DE 1,3-OXAZIN-2-AMINE FUSIONNÉE AVEC DU CYCLOPROPYLE PERFLUORÉ UTILISABLES EN TANT QU'INHIBITEURS DE LA BÊTA-SÉCRÉTASE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2014138484A1

  公开（公告）日：2014-09-12

  PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE ABSTRACT OF THE DISCLOSURE The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: INSERT STRUCTURE HERE} I wherein variables A4, A5, A6, A8, each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.

  本发明提供了一类新的化合物，用于调节β-分泌酶（BACE）活性。这些化合物具有一般的化学式I：在此插入结构} I，其中变量A4、A5、A6、A8，以及化学式I中的每个Ra、Rb、R1、R2、R3和R7，在本文中分别定义。该发明还提供了包含这些化合物的药物组合物，以及用于治疗与A-beta斑块形成和沉积相关的疾病和/或症状的化合物和组合物的用途，这些疾病和症状是由BACE的生物活性引起的。这种由BACE介导的疾病包括阿尔茨海默病、认知缺陷、认知障碍、精神分裂症和其他中枢神经系统疾病。该发明还提供了化学式II和III的化合物，以及其亚式化合物、中间体和制备本发明化合物的方法。
• DERIVATIVES OF PYRIDOXINE FOR INHIBITING HIV INTEGRASE
  申请人：Stranix Brent Richard

  公开号：US20110184028A1

  公开（公告）日：2011-07-28

  The present invention relates to compounds of Formula I or pharmaceutically acceptable salts, solvates or formulations thereof. Compounds of Formula I inhibit HIV-integrase enzyme and are useful for preventing and treating of HIV infection and AIDS.

  本发明涉及公式I的化合物或其药用可接受的盐、溶剂或配方。公式I的化合物抑制HIV整合酶酶，对预防和治疗HIV感染和艾滋病有用。
• [EN] PICOLINIC ACID DERIVATIVES AND USE THEREOF FOR TREATING DISEASES ASSOCIATED WITH ELEVATED CHOLESTEROL<br/>[FR] DÉRIVÉS D'ACIDE PICOLINIQUE ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES ASSOCIÉES À UN TAUX ÉLEVÉ DE CHOLESTÉROL
  申请人：MONTREAL HEART INST

  公开号：WO2020237374A1

  公开（公告）日：2020-12-03

  Formula I The present invention relates to compounds of Formula (I), wherein X is as defined above; Y is OR3; Z is H, optionally substituted alkyl or - CH2OR4; L is optionally substituted alkyl or heteroalkyl; R1 is H, -OH, optionally substituted alkyl, heterocycle, aryl or heteroaryl; R2 is NR5R6, or OR5; each of R3 and R4 is H or optionally substituted alkyl, benzyl, phenyl or heterocycle; or R3 and R4 combine to form an optionally substituted heterocycle; R5 is H or optionally substituted alkyl, cycloalkyl, heteroalkyl, alkylaryl or heterocycle; and R6 is H or alkyl, or pharmaceutically acceptable salts, solvates or compositions thereof. Compounds of formula (I) significantly increase low density lipoprotein receptor expression and activity, lower total circulating cholesterol and are useful for treating and delaying the onset of diseases associated with elevated cholesterol, such as atherosclerosis and hypercholesterolemia.

  本发明涉及以下式（I）的化合物，其中X如上所定义；Y为OR3；Z为H，可选择地取代的烷基或-CH2OR4；L为可选择地取代的烷基或杂环烷基；R1为H，-OH，可选择地取代的烷基，杂环烷基，芳基或杂芳基；R2为NR5R6，或OR5；R3和R4中的每一个为H或可选择地取代的烷基，苄基，苯基或杂环烷基；或R3和R4结合形成可选择地取代的杂环烷基；R5为H或可选择地取代的烷基，环烷基，杂环烷基，烷基芳基或杂环烷基；R6为H或烷基，或其药学上可接受的盐，溶剂或组合物。式（I）的化合物显著增加低密度脂蛋白受体的表达和活性，降低总循环胆固醇，并且对于治疗和延缓与胆固醇升高相关的疾病，如动脉粥样硬化和高胆固醇血症，具有用处。
• [EN] PYRROLOPYRIDINE OR PYRAZOLOPYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS PYRROLOPYRIDINE OU PYRAZOLOPYRIDINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015028483A1

  公开（公告）日：2015-03-05

  The present invention relates to compounds of formula I wherein R1 halogen, lower alkyl, lower alkoxy, cyano, phenyl, C(O)NHCH3, C(O)NH2, lower alkyl substituted by halogen or is a five-membered heteroaryl group, optionally substituted by lower alkyl; Y1 is N or CH; Y2 is CH; and if Y1 is CH, Y1 and Y2 may form together with the C-atoms to which they are attached a ring, containing −CH=N-N(CH3)-, -CH=N-N(H)-; X is CH or N; R is (CH2)m-cycloalkyl, optionally substituted by hydroxy, lower alkoxy or lower alkyl, or is tetrahydropyran, optionally substituted by hydroxy, or is lower alkoxy, substituted by hydroxy, or is lower alkyl substituted by one or two hydroxy, or is (CH2)m-pyridinyl, optionally substituted by hydroxy, lower alkyl or lower alkyl substituted by hydroxy, or is L-phenyl, optionally substituted by hydroxy, lower alkyl or lower alkyl substituted by hydroxy, and L is a bond, -CH(CH2OH)- or −CH2CH(OH)-; n is 0, 1 or 2; m is 0 or 1; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. The compounds of the present invention are muscarinic M1 receptor positive allosteric modulators (PAM) and hence are useful in the treatment of diseases, mediated by the muscarinic M1 receptor, such as Alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders.

  本发明涉及公式I的化合物，其中R1是卤素，较低的烷基，较低的烷氧基，氰基，苯基，C（O）NHCH3，C（O）NH2，被卤素取代的较低烷基或是五元杂环芳基，可选择被较低烷基取代；Y1是N或CH；Y2是CH；如果Y1是CH，则Y1和Y2可以与它们连接的C原子一起形成一个环，其中包含-CH=N-N（CH3）-，-CH=N-N（H）-；X是CH或N；R是（CH2）m-环烷基，可选择被羟基，较低烷氧基或较低烷基取代，或是四氢吡喃，可选择被羟基取代，或是被羟基取代的较低烷氧基，或是被一或两个羟基取代的较低烷基，或是（CH2）m-吡啶基，可选择被羟基，较低烷基或被羟基取代的较低烷基取代，或是L-苯基，可选择被羟基，较低烷基或被羟基取代的较低烷基取代，其中L是一个键，-CH（CH2OH）-或-CH2CH（OH）-；n是0、1或2；m是0或1；或是其对应的对映体和/或光学异构体的药学上可接受的酸加合盐或外消旋混合物。本发明的化合物是肌动蛋白M1受体正向变构调节剂（PAM），因此可用于治疗由肌动蛋白M1受体介导的疾病，例如阿尔茨海默病、认知障碍、精神分裂症、疼痛或睡眠障碍。
• HIV INTEGRASE INHIBITORS FROM PYRIDOXINE
  申请人：Stranix Brent

  公开号：US20110178120A1

  公开（公告）日：2011-07-21

  The present invention relates to pyridoxine (vitamin B 6 ) derived compounds of formula (I), pharmaceutically acceptable salts, or solvates thereof, wherein R 1 , R 2 , R 4 , A, L B 1 and B 2 are as defined in the specification, and pharmaceutical compositions comprising the compounds. Compounds of formula (I) inhibit Human Immunodeficiency Virus (HIV)-integrase enzyme and are useful for preventing and treating HIV infection and AIDS.

  本发明涉及公式（I）的吡哆醇（维生素B6）衍生物，其药学上可接受的盐或溶剂，其中R1、R2、R4、A、L、B1和B2如规范中所定义，并且包括这些化合物的药物组成物。公式（I）的化合物抑制人类免疫缺陷病毒（HIV）整合酶酶，可用于预防和治疗HIV感染和艾滋病。